1. Nussbaum ES, Djalilian HR, Cho KH, et al. Brain metastases. Histology, multiplicity, surgery, and survival. Cancer. 1996；78（8）：1781-1788
2. Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. Incidence proportions of brain metastases in patients diagnosed（1973 to 2001）in the Metropolitan Detroit Cancer Surveil-lance System. J Clin Oncol. 2004；22（14）：2865-2872
3. Takakura K, Sano K, Hojo S, et al. Pathology of metastases affecting the central nervous system. In Metastatic tumors of the central nervous system. Takakura K, Sano K, Hojo S, Hirano A, eds. Igaku-Shoin, Tokyo, 1982；pp.5- 111
4. Nakasu Y, Mitsuya K. Multidisciplinary management of brain metastases. Gan To Kagaku Ryoho. 2010；37（2）：204-210
5. Shibui S. The present status and trend of brain tumors based on the data of the Brain Tumor Regis-try of Japan. Brain Nerve. 2012；64（3）：286-290
6. Nussbaum ES, Djalilian HR, Cho KH, et al. Brain metastases. Histology, multiplicity, surgery, and survival. Cancer. 1996；78（8）：1781-1788
7. 脳腫瘍診療ガイドライン 2019 年版 日本脳腫瘍学会編 金原出版
8. Aupérin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999 Aug 12;341(7):476-84.
9. 肺癌診療ガイドライン 2020 年版 日本肺癌学会編 金原出版
10. Gondi V, Tomé WA, Mehta MP. Why avoid the hippocampus? A comprehensive review. Radiother Oncol. 2010 Dec;97(3):370-6.
11. 治療計画ガイドライン 2020 年版 日本放射線腫瘍学会金原出版
12. Gebauer J, Mehta P, Fahlbusch FB, et al. Hypothalamic-Pituitary Axis Dysfunction after Whole Brain Radiotherapy - A Cohort Study. Anticancer Res. 2020 Oct;40(10):5787-5792.
13. Gondi V, Pugh SL, Tome WA, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi- institutional trial. J Clin Oncol Off J Am Soc Clin Oncol. 2014 Dec;32(34):3810–6.
14. Pugh S, Brown P, Gondi V, et al. Hippocampal Avoidance During Whole- Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. J Clin Oncol. 2020 Apr 1;38(10):1019–29.
15. Gondi V, Tolakanahalli R, Mehta MP, et al. Hippocampal-sparing whole- brain radiotherapy: a “how-to” technique using helical tomotherapy and linear accelerator-based intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2010 Nov;78(4):1244–52.
16. Lee K, Lenards N, Holson J. Whole-brain hippocampal sparing radiation therapy: Volume-modulated arc therapy vs intensity-modulated radiation therapy case study. Med Dosim. 2016;41(1):15–21.
17. Sood S, Pokhrel D, McClinton C, et al. Volumetric-modulated arc therapy (VMAT) for whole brain radiotherapy: not only for hippocampal sparing, but also for reduction of dose to organs at risk. Med Dosim. 2017;42(4):375–83.
18. Oh SA, Yea JW, Park JW, et al. Use of a head-tilting baseplate during volumetric-modulated arc therapy (VMAT) to better protect organs at risk in hippocampal sparing whole brain radiotherapy (HS-WBRT). PLoS One. 2020;15(4):1–11.
19. Moon SY, Yoon M, Chung M, et al. Comparison of the extent of hippocampal sparing according to the tilt of a patient’s head during WBRT using linear accelerator-based IMRT and VMAT. Phys Med. 2016 May;32(5):657-63.
20. Harth S, Abo-Madyan Y, Zheng L, et al. Estimation of intracranial failure risk following hippocampal-sparing whole brain radiotherapy. Radiother Oncol. 2013 Oct;109(1):152-8.
21. Gondi V, Tome WA, Marsh J, et al. Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy: Safety profile for RTOG 0933. Radiother Oncol. 2010 Jun;95(3):327-31.
22. Kundapur V, Ellchuk T, Ahmed S, et al. Risk of hippocampal metastases in small cell lung cancer patients at presentation and after cranial irradiation: a safety profile study for hippocampal sparing during prophylactic or therapeutic cranial irradiation. Int J Radiat Oncol Biol Phys. 2015 Mar 15;91(4):781-6.
23. Yuasa M, Kurosaki H. Noncoplanar Radiation using Tomotherapy: A Phantom Study. Technol Cancer Res Treat. 2020; 19: 1533033820945776.
24. Pokhrel D, Sood S, Lominska C, et al. Potential for reduced radiation‐ induced toxicity using intensity‐modulated arc therapy for whole‐brain radiotherapy with hippocampal sparing. J Appl Clin Med Phys. 2015 Sep; 16(5): 131–141.
25. Prokic V, Wiedenmann N, Fels F, et al. Whole brain irradiation with hippocampal sparing and dose escalation on multiple brain metastases: a planning study on treatment concepts. Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):264-70.
26. García-Mollá R, de Marco-Blancas N, Bonaque J, et al. Validation of a deformable image registration produced by a commercial treatment planning system in head and neck. Phys Medica. 2015;31(3):219–23.
27. Gutiérrez AN, Westerly DC, Tomé WA, et al. Whole Brain Radiotherapy With Hippocampal Avoidance and Simultaneously Integrated Brain Metastases Boost: A Planning Study. Int J Radiat Oncol Biol Phys. 2007;69(2):589–97.
28. Shen J, Bender E, Yaparpalvi R, et al. An efficient Volumetric Arc Therapy treatment planning approach for hippocampal-avoidance whole-brain radiation therapy (HA-WBRT). Med Dosim. 2015;40(3):205–9.
29. Stoker J, Vora S, Patel A, et al. Advantages of intensity modulated proton therapy during hippocampal avoidance whole brain radiation therapy. Phys Imaging Radiat Oncol. 2018 Nov 27;8:28-32.
30. Ding X, Zhou J, Li X, et al. Improving dosimetric outcome for hippocampus and cochlea sparing whole brain radiotherapy using spot-scanning proton arc therapy. Acta Oncol. 2019 Apr;58(4):483-490.
論文の公開元へ
